RIVIERA BEACH, Fla.--(BUSINESS WIRE)--Sancilio & Company, Inc. (SCI) announced the participation of members of the leadership team at the 12th ISSFAL Congress in Stellenbosch, South Africa where several scientific presentations from the company’s current research will be delivered.
The presentations will update the research community on the preclinical and clinical work being performed to support Sancilio’s late stage development programs in critical medical conditions such as Short Bowel Syndrome (SBS), Severe Hypertriglyceridemia, and Sickle Cell Disease (SCD).
Poster and oral presentations are scheduled to be delivered as follows:
Advanced Lipid Technologies™ (ALT™) with DHA enhancing Post-Operative Growth and Intestinal Adaptation in Porcine Short Bowel Syndrome (SBS) Model.” - Session 19, Wednesday Sept. 7 (Oral presentation).
Enhancing bioavailability and reducing the food effect of Omega-3 fatty acids ethyl esters.” - Session 19, Wednesday Sept. 7 (Oral presentation).
Triglyceride lowering enhancement of Omega-3 fatty acids ethyl esters using ALT™ formulations under fasting conditions (FASTR I and FASTR II clinical studies).” – Tuesday Sept. 6 (Poster presentation #43).
Omega-3 Fatty Acids and Sickle Cell Disease, Recent Advances, and the SCOT Multicenter Randomized Clinical Trial. Wednesday Sept. 7 (Poster Presentation #91).
“ISSFAL represents a unique scientific forum to share this exciting data with the research community, said Dr. Frederick Sancilio, SCI’s CEO. We are encouraged by the findings in all these studies that support the advancement of our promising pipeline into the clinic.”
More detailed information on the meeting can be found on the conference website:
About Sancilio & Company, Inc.
Sancilio & Company, Inc. (SCI) is a fully integrated, specialty pharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products, including those based on our proprietary Advanced Lipid Technologies™ (ALT™) platform. Sancilio is pursuing treatments for sickle cell disease, short bowel syndrome and severe hypertriglyceridemia. We utilize our cGMP compliant facility to develop and manufacture our products. Our ALT™ platform is designed to enhance the bioavailability, reduce the food effect and improve the efficacy of lipids and lipophilic active pharmaceutical ingredients (APIs). Lipids are hydrophobic or amphipathic molecules, including fatty acids, steroids (including hormones) and fat-soluble vitamins (such as vitamins A, D, E and K). Our business model is to apply our ALT™ platform to lipids or lipophilic APIs to create unique product candidates that address the disorders and diseases resulting from imbalances of lipids in the body. In addition to our primary focus of developing our proprietary products using the ALT™ platform, we make use of, and license rights to, our proprietary ALT™ platform and other technologies to third parties, providing both development and subsequent soft gelatin encapsulation services as required. More information is available at: www.sancilio.com.